Calidi Biotherapeutics (CLDI) Non Operating Interest Expenses (2022 - 2026)

Calidi Biotherapeutics has reported Non Operating Interest Expenses for 5 years, with the latest figure at $29000.0 in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses changed 0.0% year-over-year to $29000.0 in Q2 2026; TTM through Jun 2026 was $126000.0, a 59.09% decrease from a year earlier, with the FY2025 full-year figure at $131000.0, down 76.65% from the prior year.
• Non Operating Interest Expenses was $29000.0 for Q2 2026 at Calidi Biotherapeutics, down from $37000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $300000.0 in Q3 2023, with the low at $29000.0 in Q3 2022.
• Average Non Operating Interest Expenses over 5 years is $133800.0, with a median of $107000.0 recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Non Operating Interest Expenses soared 934.48% in 2023, then plunged 87.33% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $100000.0 in 2022, then jumped by 200.0% to $300000.0 in 2023, then slumped by 64.33% to $107000.0 in 2024, then plunged by 65.42% to $37000.0 in 2025, then decreased by 21.62% to $29000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $29000.0 (Q2 2026), $37000.0 (Q4 2025), and $31000.0 (Q3 2025), per Business Quant data.